Erika Hamilton
MD
Director, Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute (SCRI)

Dr. Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a NCAA Postgraduate Scholarship. She then completed her medical degree and residency from University of North Carolina in Chapel Hill and fellowship training in oncology at Duke University. She joined Sarah Cannon Research Institute as investigator in drug development for women’s cancers in 2013. Since 2015 she has served as the Director of the Breast and Gynecologic Cancer Research Program. She sees patients facing breast cancer from standard of care to phase II/III to phase I drug development.

Dr. Hamilton was named to the Women to Watch Class of 2021 for Nashville Medical News. She serves on the board for local Susan G. Komen. She was selected for ASCO’s Leadership Development Class for 2021-2022, the past Chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020, and currently serves on ASCO’s Cancer Research Committee, the 2023-2025 Scientific Committee Co-Chair of the ESMO Breast Cancer Meeting and is on the Scientific Committee for AACR for 2023. She serves an Associate Editor for Clinical Breast Cancer.

Sessions

Register
General Session

Welcome

Friday, May 03, 2024
8:30 AM - 8:40 AM
General Session

Session 1: Debate: Advances in Early TNBC with Immunotherapy – Should We Continue Immunotherapy Post Surgery? - DISCUSSION

Friday, May 03, 2024
9:10 AM - 9:20 AM
General Session

Session 2: Debate: Antibody Drug Conjugates as the New Frontier: Should We Use them Sequentially? - DISCUSSION

Friday, May 03, 2024
9:50 AM - 10:00 AM
General Session

Session 3: Debate: Novel Endocrine Agents: Do PROTAC, CERAN, SERM, SERCA Really Add Anything Different Than SERDs? - DISCUSSION

Friday, May 03, 2024
11:45 AM - 11:55 AM
General Session

Session 4: Case Discussions

Friday, May 03, 2024
11:55 AM - 12:35 PM
General Session

Session 5: Case Discussions

Friday, May 03, 2024
1:45 PM - 2:25 PM
General Session

Session 6: Debate: Decisions in Early HR+ Disease: Does Age 50 Really Matter THAT Much? - DISCUSSION

Friday, May 03, 2024
2:55 PM - 3:05 PM
General Session

Session 7: Debate: HER-2 Low: Should We Even Test? - DISCUSSION

Friday, May 03, 2024
4:45 PM - 4:55 PM
General Session

Session 8: Debate: Should We Now Be Screening for HER-2 Brain Mets? - DISCUSSION

Friday, May 03, 2024
5:25 PM - 5:35 PM
General Session

Welcome

Friday, November 01, 2024
8:00 AM - 8:05 AM